Senseonics Holdings, Inc. is a medical technology company specializing in innovative glucose monitoring systems designed to improve diabetes management. Its flagship products, the Eversense 365 and Eversense E3, are continuous glucose monitoring (CGM) systems featuring a small sensor implanted under the skin that communicates with a removable smart transmitter worn externally. These systems provide real-time glucose level readings, alerts, and data via a mobile app, enabling continuous monitoring for up to 365 days with Eversense 365 and 180 days with Eversense E3 in adult patients with diabetes. Senseonics plays a significant role in the medical devices sector by offering long-term CGM solutions that support patient convenience and improved diabetes care outcomes. Founded in 2015 and headquartered in Germantown, Maryland, the company operates within the broader healthcare industry, focusing on transforming lives through advanced medical technologies.